PROTHENA CORPORATION PUBLIC LIMITED COMPANY Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $277.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-02-27
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $277.00K, a 35.88% decline from fiscal 2024.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was $432.00K.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2023 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | $277.00K 10-K · filed 2026-02-27 |
| 2024-12-31 | $432.00K 10-K · filed 2026-02-27 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |